Torrent Pharmaceuticals Limited (TORNTPHARM) — Financial Results | 23 May 2025

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Torrent Pharmaceuticals reported a 69.9% YoY revenue surge to ₹87.22 crores for Q4FY25, driven by strong domestic growth, while net profit rose 32% to ₹12.45 crores on improved margins. The company highlighted robust cash flow generation and reaffirmed its commitment to sustainable growth in emerging markets.

📄 View Original Announcement (PDF)

About Torrent Pharmaceuticals Limited (TORNTPHARM)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,49,108.91 Cr P/E: 80.1

View full TORNTPHARM stock details →

📡 Get AI alerts when TORNTPHARM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track TORNTPHARM — Free

📊 More TORNTPHARM filings

See all TORNTPHARM filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when TORNTPHARM files new disclosures

Track TORNTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track TORNTPHARM — Free

Free account · 2 AI queries/day